Mn Services Vermogensbeheer B.V. Has $43.34 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Mn Services Vermogensbeheer B.V. lessened its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 3.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 219,603 shares of the company's stock after selling 6,900 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Zoetis were worth $43,343,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. Blue Bell Private Wealth Management LLC lifted its stake in shares of Zoetis by 222.5% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company's stock valued at $25,000 after buying an additional 89 shares during the period. Evermay Wealth Management LLC lifted its stake in shares of Zoetis by 439.3% during the 1st quarter. Evermay Wealth Management LLC now owns 151 shares of the company's stock worth $25,000 after purchasing an additional 123 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its stake in shares of Zoetis by 430.8% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company's stock worth $26,000 after purchasing an additional 112 shares during the period. Worth Asset Management LLC acquired a new stake in shares of Zoetis during the first quarter worth $26,000. Finally, VisionPoint Advisory Group LLC purchased a new stake in shares of Zoetis in the second quarter valued at $29,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Insider Activity

In related news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction on Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the sale, the executive vice president now owns 15,723 shares of the company's stock, valued at approximately $2,725,267.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders sold 2,209 shares of company stock worth $408,453. 0.12% of the stock is currently owned by company insiders.

Zoetis Stock Down 7.8 %

Zoetis stock traded down $12.75 during trading on Friday, reaching $149.98. 11,577,753 shares of the company's stock were exchanged, compared to its average volume of 3,015,519. Zoetis Inc. has a 52-week low of $148.48 and a 52-week high of $201.92. The firm has a market cap of $68.59 billion, a price-to-earnings ratio of 29.58, a PEG ratio of 2.48 and a beta of 0.85. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. The company's 50-day moving average is $179.92 and its two-hundred day moving average is $180.87.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.32 by ($0.08). The company had revenue of $2.21 billion during the quarter, compared to analysts' expectations of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. Zoetis's quarterly revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.15 EPS. On average, analysts predict that Zoetis Inc. will post 5.8 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.15%. Zoetis's payout ratio is currently 34.12%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ZTS shares. Barclays raised their price target on Zoetis from $255.00 to $260.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 14th. Stifel Nicolaus dropped their price target on shares of Zoetis from $215.00 to $195.00 and set a "buy" rating for the company in a research report on Tuesday, April 2nd. StockNews.com downgraded shares of Zoetis from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, February 20th. Jefferies Financial Group restated a "buy" rating and set a $230.00 price objective on shares of Zoetis in a report on Tuesday, December 19th. Finally, Piper Sandler lifted their target price on Zoetis from $215.00 to $220.00 and gave the company an "overweight" rating in a report on Tuesday, February 20th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $224.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.